May 21, 2013 ·
Leave a comment
Thought Leader Select is pleased to announce its sponsorship of the upcoming Canadian Business Association event featuring former Quintiles chief Sandy Costa.
Founded in 2009 by a group of Canadian business leaders based in the state’s Research Triangle region, the Canadian Business Association of North Carolina (CBANC) is an exchange where business leaders meet to share knowledge, connect, network, and build awareness of the significance of the US-Canadian relationship. CBANC produces a number of events featuring prominent Canadians, including executives and politicians.
The latest event, slated for June 5 at 5:30 pm at the RTP campus of Medicago USA, features Santo J. “Sandy” Costa, a former executive at Glaxo, Inc. (now GlaxoSmithKline) and Quintiles Transnational Corp in the Triangle. An acclaimed author, speaker, and attorney, Mr. Costa’s business experience includes over 40 years in various executive roles in the pharmaceutical, health care, and life sciences industries, as well as time spent as a practicing attorney.
Mr. Costa currently serves as Of Counsel to the law firm Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan of Raleigh. In addition to his ongoing professional work as an attorney, Mr. Costa serves on several boards of directors for publicly-traded and privately-held companies.
Mr. Costa continues to impact the Triangle area on a number of fronts, serving as an adjunct professor in the clinical research program at ... read more »
TAGS: 
Campbell University School of Pharmacy Canadian Business Association of North Carolina CBANC Duke Brain Tumor Center Duke Cancer Patient Support Program Glaxo health care industry life sciences industry Paul Meade pharmaceutical industry Quintiles Research Triangle Sandy Costa Thought Leader Select UNC Thurston Arthritis Research Center
October 25, 2012 ·
Leave a comment
Thought Leader Select is a company focused on driving industry collaborations among biopharmaceutical, medical device, and diagnostics companies with leading medical experts and centers of excellence, with the ultimate goals of these collaborations being two-fold in purpose: better treatment options for patients and better outcomes for global public health. As part of our company’s mission, we work with multiple organizations to promote best practices that deliver ethical, transparent interactions among these various healthcare constituencies.
One of these groups is the recently-launched Medical Science Liaison Society, a global Non-Profit organization being led by the Chairman of the Board, Dr. Samuel Dyer. The MSL Society is filling a vital need for the expanding role of Medical Science Liaisons around the world, as they collaborate with KOLs, physicians, and other health care professionals to advance medical science together to improve the quality of life for patients everywhere.
Thought Leader Select’s Allison Murphy, a veteran MSL herself from her days working in the Endocrinology Medical Affairs unit at Eli Lilly and Company, recently sat down with Dr. Dyer to learn more about this emerging organization and the impact the MSL Society is
having in promoting the role of Medical Science Liaisons in the pharmaceutical, biopharmaceutical, medical device, and diagnostics industries.
Allison Murphy: ... read more » TAGS: Allison Murphy biopharmaceutical companies centers of excellence diagnostics companies Eli Lilly and Company EyeforPharma First Word global MSL community key opinion leader management key opinion leader relationships KOL compliance L&M Association Management medical affairs medical affairs executives medical device companies medical experts Medical Science Liaison Society medical science liaisons MSL conferences MSL podcasts MSL webinars MSL white papers non-profit association pharmaceutical industry Samuel Dyer Thought Leader Select
December 10, 2010 ·
Leave a comment
Industry Insights from Paul Meade, M.Sc, MPH
For decades, the pharmaceutical industry has had a good working relationship with the medical profession. Of course, pharmaceutical companies have always been dependent on physicians writing prescriptions for their products, and for pharmacists filling these prescriptions, so ultimately the patients could return to health. This has been a true symbiotic relationship where pharmaceutical companies needed doctors to prescribe their drugs, and physicians had effective medicines to offer their patients.
Occasionally, there were a few bad apples on both sides of the equation that overstepped the boundaries of this relationship, but for the most part, it worked well. So what happened? Why the Sunshine Act? And why the apparent “witch-hunt” to expose every Thought Leader that engages with someone from a pharmaceutical company? Is it time for a course correction? Don’t we have bigger problems to deal with in the financial and economic arenas than to worry about how much money a Thought Leader made from conducting clinical studies or speaking at a conference on behalf of a pharmaceutical company?
Where did it all go wrong? How do we fix it? And what does the future hold for this pharma-medical relationship? Healthcare costs have been steadily rising in most countries across the globe. And while there have been increases in these costs, almost no other country has ... read more »
TAGS: compensation drug companies ethics healthcare healthcare bill healthcare reform medical professionals pharma pharma-medical relationship pharmaceutical companies pharmaceutical industry pharmacists physicians prescriptions Sunshine Act thought leader
